MedPage Today on MSN
Targeted duo wins again in BRAF-mutant colorectal cancer
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...
Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports We demonstrate dynamic evolution of resistance ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...
A retrospective observational study to evaluate the efficacy of trifluridine/tipiracil ± bevacizumab in metastatic colorectal cancer with MSI-high/deficient MMR. This is an ASCO Meeting Abstract from ...
LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...
A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability (MSI) and BRAF and KRAS mutation status when determining the prognosis of patients with ...
Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback